Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
James Chih‐Hsin Yang(National Taiwan University Hospital), Yi‐Long Wu(Guangdong General Hospital), Martin Schüler, Martin Sebastian(Goethe University Frankfurt), Sanjay Popat(Royal Marsden Hospital), Nobuyuki Yamamoto(Wakayama Medical University), Caicun Zhou(Shanghai Pulmonary Hospital), Cheng-Ping Hu(Central South University), Kenneth J. O’Byrne(Queensland University of Technology), Jifeng Feng(Jiangsu Cancer Hospital), Shun Lü(Shanghai Chest Hospital), Yunchao Huang(Kunming Medical University), Sarayut Lucien Geater(Prince of Songkla University), Kye Young Lee(Konkuk University Medical Center), Chun-Ming Tsai(Taipei Veterans General Hospital), В. А. Горбунова, Vera Hirsh(McGill University), Jaafar Bennouna(Institut de Cancérologie de l'Ouest), С. В. Орлов(First Pavlov State Medical University of St. Petersburg), Tony Mok(Chinese University of Hong Kong), Michael Boyer(Royal Prince Alfred Hospital), Wu‐Chou Su(National Cheng Kung University Hospital), Ki Hyeong Lee(Konkuk University Medical Center), Terufumi Kato(Kanagawa Cardiovascular and Respiratory Center), Dan Massey(Boehringer Ingelheim (United Kingdom)), Mehdi Shahidi(Boehringer Ingelheim (United Kingdom)), Victoria Zazulina(Boehringer Ingelheim (United Kingdom)), Lecia V. Sequist(Harvard University)
Cited by 1,578